Viking Therapeutics
Stock Forecast, Prediction & Price Target
Viking Therapeutics (VKTX) stock Price Target by analysts
$98
Potential upside: 301.63%
Viking Therapeutics price prediction
What is Viking Therapeutics stock analysts` prediction?
Viking Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for Viking Therapeutics in the last 3 months, the avarage price target is $98, with a high forecast of $NaN. The average price target represents a 301.63% change from the last price of $24.4.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Viking Therapeutics stock Price Target by analysts
Full breakdown of analysts given Viking Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Biren Amin Piper Sandler | 0% 0/1 | 9 months ago | $74 203.27% upside | $52.94 | StreetInsider | Previous targets (0) |
Yale Jen Laidlaw | 0% 0/1 | 10 months ago | $110 350.81% upside | $63.14 | StreetInsider | Previous targets (0) |
Roger Song Jefferies | 0% 0/1 | 10 months ago | $110 350.81% upside | $63.14 | StreetInsider | Previous targets (0) |
Michael Ulz Morgan Stanley | 0% 0/1 | about 1 year ago | $105 330.32% upside | $47.39 | TheFly | Previous targets (0) |
Joseph Pantginis H.C. Wainwright | 50% 1/2 | about 1 year ago | $90 268.85% upside | $52.12 | StreetInsider | Previous targets (1) |
Joon Lee Truist Financial | 0% 0/1 | over 1 year ago | $120 391.80% upside | $69.53 | TheFly | Previous targets (0) |
Steve Seedhouse Raymond James | 0% 0/1 | over 1 year ago | $116 375.40% upside | $69.06 | StreetInsider | Previous targets (0) |
Justin Zelin BTIG | 33.33% 1/3 | over 1 year ago | $125 412.29% upside | $83.98 | StreetInsider | Previous targets (2) |
Samimy Annabel Stifel Nicolaus | 0% 0/1 | over 1 year ago | $95 289.34% upside | $83.87 | StreetInsider | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/1 | over 1 year ago | $138 465.57% upside | $80.83 | StreetInsider | Previous targets (0) |
Justin Zelin BTIG | 33.33% 1/3 | over 1 year ago | $100 309.83% upside | $62.56 | StreetInsider | Previous targets (2) |
Maxim Maxim Maxim Group | 100% 1/1 | over 2 years ago | $15 -38.52% downside | $8.45 | Pulse 2.0 | Previous targets (0) |
Joseph Pantginis H.C. Wainwright | 50% 1/2 | over 2 years ago | $21 -13.93% downside | $6.37 | TheFly | Previous targets (1) |
Justin Zelin BTIG | 33.33% 1/3 | over 2 years ago | $20 -18.03% downside | $6.72 | TheFly | Previous targets (2) |
Viking Therapeutics Financial Estimates
Viking Therapeutics Revenue Estimates
Viking Therapeutics EBITDA Estimates
Viking Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $777.14K Low: $777.14K High: $777.14K avg. 0% | Avg: $38.10M Low: $38.10M High: $38.10M avg. 4802.71% | Avg: $124.95M Low: $124.95M High: $124.95M avg. 227.95% | Avg: $553.86M Low: $553.86M High: $553.86M avg. 343.26% |
Net Income
% change YoY
| $-54.00M N/A | $-67.37M -24.77% | $-85.89M -27.48% | Avg: $-171.37M Low: $-199.07M High: $-90.57M avg. -99.51% | Avg: $-192.32M Low: $-252.84M High: $-31.13M avg. -12.22% | Avg: $-132.19M Low: $-132.19M High: $-132.19M avg. 31.26% | Avg: $49.81M Low: $49.81M High: $49.81M avg. 137.68% |
EBITDA
% change YoY
| $-55.68M N/A | $-70.31M -26.26% | $-100.82M -43.39% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$0.7 N/A | -$0.88 -25.71% | -$0.91 -3.40% | Avg: -$1.55 Low: -$2.11 High: -$0.96 avg. -70.10% | Avg: -$1.7 Low: -$2.68 High: -$0.33 avg. -9.67% | Avg: -$1.4 Low: -$1.4 High: -$1.4 avg. 17.47% | Avg: $0.53 Low: $0.53 High: $0.53 avg. 137.68% |
Operating Expenses
% change YoY
| $55.68M N/A | $70.35M 26.35% | $100.82M 43.31% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Viking Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 14.30% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -199.07M, average is -171.37M and high is -90.57M.
What is Viking Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1343.48% in 2025-2028.
We have gathered data from 10 analysts. Their low revenue estimate is $777.14K, average is $777.14K and high is $777.14K.
What is Viking Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 18.84% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$2.11, average is -$1.55 and high is $-0.96.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Viking Therapeutics stock. The most successful analyst is Biren Amin.